



IBA Lifesciences GmbH
Rudolf-Wissell-Str. 28
37079 Goettingen
Germany
Tel.: +49 (0) 551-5 06 72-0
E-mail: info@iba-lifesciences.com
www.iba-lifesciences.com

Data Sheet

pCSG-IBAwt2

Cat. No.: 5-5001-001

Version: 3.0
Revision Date: 28.07.2021

| | |
|-------------------------|--|
| Description | StarGate Acceptor Vector for transient expression as well as for generation of stable mammalian cell lines. Extrachromosomal replication in mammalian cells could occur either by origin of replication from Epstein-Barr Virus (oriP) or by SV40 ori. For the former the vector provides the EBNA-1 gene and for the latter the cell line has to be latently infected with SV40 or express the SV40 large T antigen (e.g., HEK293T, COS-1, COS-7). Stable cell lines can be selected by the neomycin resistance gene (NeoR). In addition, the human cytomegalovirus (CMV) immediate-early promoter enables a high-level expression in a wide range of mammalian cells. The expressed recombinant protein will be secreted into the medium. |
| Affinity tag | no affinity tag |
| Secretion | BM40 secretory signal peptide is encoded for the transfer of the expressed protein into the medium. During the translocation the signal peptide is removed by endogenous proteases. |
| Cloning Strategy | Cloning into StarGate Acceptor Vectors has to be done with the restriction enzyme Esp3I. There is no Multiple Cloning Site (MCS) available that can be used for the integration of the gene of interest instead (see manual). |
| Resistance | Ampicillin: for selection of transformed E. coli cells Neomycin: for selection of stable cell lines |
| Form | 5 µg, dissolved in 20 µl TE buffer, pH 8.0: 10 mM Tris/HCl, 1 mM EDTA |
| Concentration | 250 ng/µl |
| Stability | 12 months after shipping |
| Storage | recommended: 2-8 °C for frequent usage, -20 °C for long-term storage |
| Shipping | room temperature |
| Hazards | Product is not classified as hazardous according to (EC) No 1272/2008 [CLP]. A Material Safety Data Sheet is provided. |

For research use only


Trademark information

The owners of trademarks marked by “®” or “TM” are identified at <http://www.iba-lifesciences.com/patents.html>. Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.


Important licensing information

This product is covered by intellectual property (IP) rights and on completion of the sale IBA Lifesciences grants respective Limited Use Label Licenses to purchaser. IP rights and Limited Use Label Licenses for said technology are further described and identified at <http://www.iba-lifesciences.com/patents.html> or upon inquiry at info@iba-lifesciences.com or at IBA Lifesciences GmbH, Rudolf-Wissell-Str. 28, 37079 Goettingen, Germany. By use of this product the purchaser accepts the terms and conditions of all applicable Limited Use Label Licenses.

Expression cassette of pCSG-IBAwt2



LacP/Z cassette = contains LacZ alpha fragment under control of a separate promoter, which allows alpha complementation of *LacZ* mutations such as *LacZ* Δ M15 as in *E. coli* DH5 α or TOP10.
 your protein = after StarGate cloning using *Esp3I* your gene of interest will be located here



| Features | from bp | to bp | Sequencing primer |
|-----------------------------------|---------|-------|--|
| polyA signal sequence | 1 | 213 | ESG/CSG-Primer-for 5' - GAGAACCCACTGCTTACTGGC -3' |
| f1 origin | 259 | 687 | |
| SV40 ori | 692 | 1035 | ESG/CSG-Primer-rev 5' - TAGAAGGCACAGTCGAGG -3' |
| Neomycin resistance gene | 1097 | 1891 | |
| ColEI ori | 2637 | 3222 | |
| Ampicillin resistance gene | 4253 | 3393 | |
| EBNA-1 | 4944 | 6869 | |
| oriP, episomal replication origin | 7170 | 9145 | |
| CMV promoter | 9426 | 10013 | |
| forward primer binding site | 10026 | 10046 | |
| BM40 signal sequence | 10089 | 10142 | |
| LacZ alpha fragment | 10371 | 10772 | |
| reverse primer binding site | 10903 | 10920 | |
| total vector length | | 10920 | |